论文部分内容阅读
蒽环类药物以其卓越的疗效成为乳腺癌术后辅助化疗的里程碑。多项随机临床试验结果表明:含蒽环类药物方案的辅助化疗可提高生存率,降低复发率和死亡率。近年研究还显示,蒽环类药物尤其使HER-2和Top-Ⅱ共同扩增的患者获益更大。蒽环类药物疗效确切,相关毒性可预测和预防,性价比更佳。蒽环类药物仍然是乳腺癌术后辅助化疗的基石,在辅助治疗中仍占有重要的地位。
Anthracycline has become a milestone in postoperative adjuvant chemotherapy for breast cancer with its excellent efficacy. A number of randomized clinical trials have shown that adjuvant chemotherapy with an anthracycline regimen increases survival and reduces relapse and mortality. Recent studies have also shown that anthracyclines benefit in particular by co-amplification of HER-2 and Top-II. Anthracycline effective curative effect, related toxicity can be predicted and prevented, cost-effective better. Anthracycline is still the cornerstone of postoperative adjuvant chemotherapy for breast cancer and still plays an important role in adjuvant therapy.